151 related articles for article (PubMed ID: 30745338)
1. Synthetic lethality of cytolytic HSV-1 in cancer cells with ATRX and PML deficiency.
Han M; Napier CE; Frölich S; Teber E; Wong T; Noble JR; Choi EHY; Everett RD; Cesare AJ; Reddel RR
J Cell Sci; 2019 Mar; 132(5):. PubMed ID: 30745338
[TBL] [Abstract][Full Text] [Related]
2. ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.
Brosnan-Cashman JA; Yuan M; Graham MK; Rizzo AJ; Myers KM; Davis C; Zhang R; Esopi DM; Raabe EH; Eberhart CG; Heaphy CM; Meeker AK
PLoS One; 2018; 13(9):e0204159. PubMed ID: 30226859
[TBL] [Abstract][Full Text] [Related]
3. Atrx deletion impairs CGAS/STING signaling and increases sarcoma response to radiation and oncolytic herpesvirus.
Floyd W; Pierpoint M; Su C; Patel R; Luo L; Deland K; Wisdom AJ; Zhu D; Ma Y; DeWitt SB; Williams NT; Lazarides AL; Somarelli JA; Corcoran DL; Eward WC; Cardona DM; Kirsch DG
J Clin Invest; 2023 Jul; 133(13):. PubMed ID: 37200088
[TBL] [Abstract][Full Text] [Related]
4. ATRX Alteration Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas.
Darmusey L; Pérot G; Thébault N; Le Guellec S; Desplat N; Gaston L; Delespaul L; Lesluyes T; Darbo E; Gomez-Brouchet A; Richard E; Baud J; Leroy L; Coindre JM; Blay JY; Chibon F
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946962
[TBL] [Abstract][Full Text] [Related]
5. Correction: Distinct temporal roles for the promyelocytic leukaemia (PML) protein in the sequential regulation of intracellular host immunity to HSV-1 infection.
Alandijany T; Roberts APE; Conn KL; Loney C; McFarlane S; Orr A; Boutell C
PLoS Pathog; 2018 Feb; 14(2):e1006927. PubMed ID: 29470515
[TBL] [Abstract][Full Text] [Related]
6. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
7. The HSV-1 ubiquitin ligase ICP0: Modifying the cellular proteome to promote infection.
Rodríguez MC; Dybas JM; Hughes J; Weitzman MD; Boutell C
Virus Res; 2020 Aug; 285():198015. PubMed ID: 32416261
[TBL] [Abstract][Full Text] [Related]
8. TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling.
Heiniö C; Havunen R; Santos J; de Lint K; Cervera-Carrascon V; Kanerva A; Hemminki A
Cells; 2020 Mar; 9(4):. PubMed ID: 32225009
[TBL] [Abstract][Full Text] [Related]
9. Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas.
Omar NB; Bentley RT; Crossman DK; Foote JB; Koehler JW; Markert JM; Platt SR; Rissi DR; Shores A; Sorjonen D; Yanke AB; Gillespie GY; Chambers MR
Neurosurg Focus; 2021 Feb; 50(2):E5. PubMed ID: 33524948
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective.
Ramelyte E; Tastanova A; Balázs Z; Ignatova D; Turko P; Menzel U; Guenova E; Beisel C; Krauthammer M; Levesque MP; Dummer R
Cancer Cell; 2021 Mar; 39(3):394-406.e4. PubMed ID: 33482123
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice.
Syed Najmuddin SUF; Amin ZM; Tan SW; Yeap SK; Kalyanasundram J; Veerakumarasivam A; Chan SC; Chia SL; Yusoff K; Alitheen NB
PeerJ; 2020; 8():e9761. PubMed ID: 33354412
[TBL] [Abstract][Full Text] [Related]
12. Anti-viral immunity in the tumor microenvironment: implications for the rational design of herpes simplex virus type 1 oncolytic virotherapy.
Rider PJF; Uche IK; Sweeny L; Kousoulas KG
Curr Clin Microbiol Rep; 2019 Dec; 6(4):193-199. PubMed ID: 33344108
[TBL] [Abstract][Full Text] [Related]
13. Antitumor Efficacy of Oncolytic Herpes Virus Type 1 Armed with GM-CSF in Murine Uveal Melanoma Xenografts.
Liu S; Liu F; Zhao M; Zhang J
Cancer Manag Res; 2020; 12():11803-11812. PubMed ID: 33239914
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic herpes simplex virus type 1 (HSV-1) in combination with lenalidomide for plasma cell neoplasms.
Oku M; Ishino R; Uchida S; Imataki O; Sugimoto N; Todo T; Kadowaki N
Br J Haematol; 2021 Jan; 192(2):343-353. PubMed ID: 33216988
[TBL] [Abstract][Full Text] [Related]
15. Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of
Froechlich G; Caiazza C; Gentile C; D'Alise AM; De Lucia M; Langone F; Leoni G; Cotugno G; Scisciola V; Nicosia A; Scarselli E; Mallardo M; Sasso E; Zambrano N
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33213060
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of an oncolytic measles virus against canine urinary bladder transitional cell carcinoma cells.
Iizuka K; Shoji K; Fujiyuki T; Moritoh K; Tamura K; Yoshida A; Sato H; Yoneda M; Asano K; Kai C
Res Vet Sci; 2020 Dec; 133():313-317. PubMed ID: 33183781
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1.
Kim KJ; Moon D; Kong SJ; Lee YS; Yoo Y; Kim S; Kim C; Chon HJ; Kim JH; Choi KJ
Gene Ther; 2021 Apr; 28(3-4):186-198. PubMed ID: 33149278
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of a third-generation oncolytic herpes simplex viral therapy for an HPV-related uterine cervical cancer model.
Kagabu M; Yoshino N; Saito T; Miura Y; Takeshita R; Murakami K; Kawamura H; Baba T; Sugiyama T
Int J Clin Oncol; 2021 Mar; 26(3):591-597. PubMed ID: 33146805
[TBL] [Abstract][Full Text] [Related]
19. Methods for the Construction of Recombinant Oncolytic Myxoma Viruses.
Torres-Domínguez LE; de Matos AL; Rahman MM; McFadden G
Methods Mol Biol; 2021; 2225():63-75. PubMed ID: 33108657
[TBL] [Abstract][Full Text] [Related]
20. Identification of oncolytic vaccinia restriction factors in canine high-grade mammary tumor cells using single-cell transcriptomics.
Cambien B; Lebrigand K; Baeri A; Nottet N; Compin C; Lamit A; Ferraris O; Peyrefitte CN; Magnone V; Henriques J; Zaragosi LE; Giorgetti-Peraldi S; Bost F; Gautier-Isola M; Rezzonico R; Barbry P; Barthel R; Mari B; Vassaux G
PLoS Pathog; 2020 Oct; 16(10):e1008660. PubMed ID: 33075093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
